Stefano Gentileschi, Carla Gaggiano, Arianna Damiani, Carmela Coccia, Pamela Bernardini, Massimiliano Cazzato, Francesco D'Alessandro, Giulia Vallifuoco, Riccardo Terribili, Marco Bardelli, Caterina Baldi, Luca Cantarini, Marta Mosca, Bruno Frediani, Serena Guiducci
Inhibiting Janus Kinases (JAK) is a crucial therapeutic strategy in rheumatoid arthritis (RA). However, the use of JAK inhibitors has recently raised serious safety concerns. The study aims to evaluate the safety profile of JAKi in patients with RA and identify potential risk factors (RFs) for adverse events (AEs). Data of RA patients treated with JAKi in three Italian centers from January 2017 to December 2022 were retrospectively analyzed. 182 subjects (F:117, 64.3%) underwent 193 treatment courses. 78.6% had at least one RF, including age ≥ 65 years, obesity, smoking habit, hypertension, dyslipidemia, hyperuricemia, diabetes, previous VTE or cancer, and severe mobility impairment...
March 30, 2024: Clinical and Experimental Medicine